The Ibogaine Experience: Hour by Hour — What Really Happens During Treatment

There is no way to fully prepare someone for what ibogaine feels like. I can describe the pharmacology — how ibogaine binds to opioid receptors, modulates glutamate signaling, and upregulates glial cell line-derived neurotrophic factor (GDNF). I can walk you through the clinical data, the safety protocols, the blood panels and EKGs that precede every treatment.

But the experience itself — the hours inside the medicine — that lives in a different category of human knowledge. It is felt, not explained. Still, patients deserve to know what lies ahead. Over the past several years at MindScape Retreat, I have guided hundreds of individuals through ibogaine treatment.

Each journey is unique, but the arc is remarkably consistent. There is a pattern to how the medicine moves through the body, the mind, and — if we are being honest about what patients report — the soul. What follows is the most honest account I can give of what happens, hour by hour, when someone undergoes ibogaine treatment. Before the Clock Starts: Preparation That Matters The ibogaine experience does not begin when you swallow the capsule.

It begins days or weeks earlier, during the medical screening process that determines whether you are a safe candidate for treatment. At MindScape, every patient undergoes a comprehensive intake that includes a full metabolic panel, liver function tests, a 12-lead electrocardiogram, and a thorough review of medication history. We are looking for contraindications — prolonged QT interval, significant hepatic impairment, certain psychiatric medications that interact dangerously with ibogaine's metabolism through the CYP2D6 enzyme pathway (Koenig & Hilber, 2015). This is not a ceremony you walk into casually.

It is a medical procedure wrapped in a profound psychological experience, and the medical dimension comes first. In the 48 to 72 hours before treatment, patients follow a clean diet — no processed foods, no caffeine, no alcohol, minimal sugar. For those detoxing from opioids, we work with precise timing to ensure short-acting opioids have cleared sufficiently while managing withdrawal symptoms that may already be present. The physical body needs to be as stable as possible before we introduce the medicine.

Then there is the mindset. I spend time with every patient the evening before their session. We talk about intention — not in a vague, spiritual sense, but in a concrete one. What brought you here?

What are you most afraid of? What do you need to let go of? These conversations are not performative. Research on psychedelic-assisted therapy consistently shows that set and setting profoundly influence outcomes (Carhart-Harris et al.

, 2018). The mind you bring into the experience shapes the experience you have. By the time morning arrives and the patient is lying in our treatment room with cardiac monitors attached, an IV line placed, and a nurse within arm's reach, we have done everything medically and psychologically possible to prepare the ground. What happens next is between them and the medicine.

Hour 0 to 2: The Onset The flood dose is administered orally — typically a combination of total alkaloid extract (TA) and purified ibogaine hydrochloride (HCL), a protocol unique to MindScape that I will explain in more detail shortly. Within 30 to 45 minutes, the first signs of onset appear. Patients describe a heaviness settling into the body. The limbs feel dense, almost leaden.

There is often a buzzing or vibrating sensation that starts in the extremities and moves inward — some describe it as feeling like every cell in the body is humming at a slightly different frequency. Ataxia sets in; if a patient tries to stand (which we discourage), they will find their coordination significantly impaired. The vestibular system is being affected, and with it comes the characteristic sensitivity to movement. Even turning the head can trigger waves of nausea.

This is the phase where anxiety tends to peak. The body is entering a state it has never experienced before, and the autonomic nervous system responds accordingly. Heart rate may increase slightly before settling. We monitor QTc interval continuously during this window because the first two hours carry the highest cardiac risk profile (Alper et al.

, 2012). At MindScape, a physician is present throughout, not down the hall, not on call — in the room. The visual field begins to shift around the 60 to 90 minute mark. With eyes closed, patients report geometric patterns, flickering lights, or a sense that the darkness behind their eyelids has texture and depth.

The mind is transitioning from ordinary waking consciousness into something quite different. The medicine is crossing the blood-brain barrier in force, and the noribogaine metabolite — which will sustain the experience for hours to come — is beginning to accumulate. By the end of hour two, most patients have surrendered to the process. The body has become very still.

Speech becomes effortful. The outside world — the room, the monitors, the nurse checking vitals — recedes into background awareness. What opens in its place is the visionary phase. Hour 2 to 6: The Acute Visionary Phase This is the period that most people are thinking about when they ask, "What does ibogaine feel like?

" It is also the hardest to describe. With eyes closed, patients enter a state of vivid, immersive inner experience that bears little resemblance to dreaming and even less to ordinary imagination. The visions reported under ibogaine are distinctive in their narrative quality. Unlike psilocybin or DMT, which often produce abstract geometric or cosmic imagery, ibogaine tends to generate what researchers have called "waking dream" states — coherent, autobiographical sequences that feel as real as lived memory (Schenberg et al.

, 2017). Patients frequently report seeing scenes from their childhood with photographic clarity. A kitchen they haven't thought about in thirty years. The face of a grandparent.

The exact quality of afternoon light coming through a window in a house they lived in at age four.

It is a medical procedure wrapped in a profound psychological experience, and the medical dimension comes first.

These are not metaphors or symbols; patients describe them as literal re-experiences, as though the brain has pulled archived footage from deep storage and is playing it back in high definition. Within these scenes, emotional processing occurs at a depth that is difficult to achieve in years of conventional therapy. A patient who was physically abused as a child may re-experience a specific incident — but this time, they witness it from outside, with the understanding and compassion of their adult self.

They see the fear in the child's eyes and the pain driving the abuser's behavior simultaneously. It is not re-traumatization; it is re-contextualization. Patients emerge from these sequences saying things like, "I finally understand why I've been carrying this weight," or "I forgave my father — not because what he did was okay, but because I saw that he was broken too. " Not all visions are biographical.

Some patients report encounters with entities, ancestral figures, or symbolic representations of their addiction. Opioid-dependent patients have described seeing their addiction as a physical thing — a parasite, a shadow, a structure built inside their body — and watching the medicine dismantle it piece by piece. Others describe traveling through landscapes that feel deeply meaningful without any rational explanation for why. Throughout this phase, the body remains very still.

Patients may appear to be sleeping, but their brain activity tells a different story. They are conscious, aware, and processing at an extraordinary rate. Occasionally they will speak — a few words, a name, sometimes tears. We keep the room dark and quiet.

External stimulation is minimized. The medicine is doing its work, and the best thing we can do is protect the space. Physiologically, this is also when ibogaine is exerting its most powerful neurochemical effects. The molecule is binding to NMDA receptors, kappa-opioid receptors, sigma receptors, and serotonin transporters simultaneously — a pharmacological profile unlike any other known substance (Glick et al.

, 2001). For opioid-dependent patients, ibogaine is resetting the receptor landscape in real time. By the time the visionary phase ends, many patients will find that their withdrawal symptoms have vanished entirely. Hour 6 to 12: The Evaluative Phase As the acute visions begin to subside, patients enter what I call the evaluative or introspective phase.

The cinematic quality of the earlier hours gives way to something more like an internal dialogue — a state of profound clarity in which the insights gained during the visionary phase are processed, organized, and integrated. Patients often describe this as the most therapeutically valuable period. The emotional intensity has decreased, but the cognitive clarity is extraordinary. It is as though the usual mental noise — the anxious loops, the self-defeating narratives, the compulsive thought patterns — has been turned off, and what remains is a quiet, honest assessment of one's life.

During these hours, patients think about their relationships, their choices, the trajectories they have been on, and the trajectories they want to pursue. They are not doing this in the abstract. They are doing it with the emotional material that the visionary phase excavated. The childhood memories, the traumas, the moments of joy and connection that had been buried under years of substance use or psychological defense — all of this is now on the table, visible and available for examination.

I often sit with patients during this phase if they want to talk. The conversations that happen between hours eight and twelve are some of the most profound I have ever witnessed in clinical practice. People speak with a directness and self-awareness that would be remarkable under any circumstances, but is extraordinary coming from someone who, twelve hours ago, was in the grip of opioid withdrawal or crippling PTSD. The body is beginning to recover its ordinary functioning during this period.

Nausea typically resolves by hour eight. Motor coordination slowly returns, though patients remain in bed. The cardiac monitoring continues — noribogaine has a long half-life, and QTc prolongation can persist — but the acute risk window has passed. Vital signs are stable.

The medicine has done the heavy neurochemical lifting. Now it is sustaining a state that allows the psyche to do its work. Hour 12 to 24: Residual Stimulation By the twelve-hour mark, most of the visionary and introspective content has resolved. What remains is a state of gentle wakefulness that patients often find surprising.

Despite having been through what many describe as the most intense experience of their lives, they do not feel exhausted in the way one might expect. There is a residual stimulation — a quiet alertness that makes sleep difficult but does not feel unpleasant. This is primarily the work of noribogaine, ibogaine's primary metabolite, which has a half-life of 24 to 48 hours and continues to exert effects on the serotonin transporter and opioid receptor systems long after the parent compound has been cleared (Mash et al. , 2000).

Patients describe feeling clean — as though a film has been removed from their perceptions. Colors look brighter. Sounds are crisper. There is often a sense of being returned to a baseline state of consciousness that they have not experienced since before their addiction began.

During these hours, patients may reflect quietly, listen to music, or simply rest with eyes open. We encourage them to eat when they feel ready — often the first food in over 24 hours. The body is hungry, and there is something grounding about the simple act of nourishing oneself after such a profound inner journey. Sleep eventually comes, usually around hour 18 to 24, and it tends to be deep and restorative.

We continue monitoring through the night. By morning, most patients are ready to sit up, walk to the bathroom unassisted, and begin the first conversations about what they experienced. The MindScape Protocol: Why TA Plus HCL Changes the Experience Most ibogaine clinics administer a single flood dose of either total alkaloid extract (TA) or purified ibogaine hydrochloride (HCL). At MindScape, we use a combined protocol that leverages the strengths of both forms, followed by carefully timed booster doses.

Total alkaloid extract contains the full spectrum of iboga alkaloids — not just ibogaine, but also ibogaline, ibogamine, tabernanthine, and several dozen other compounds that occur naturally in the Tabernanthe iboga root bark. These companion alkaloids modulate the experience in ways that purified HCL alone cannot replicate. Patients who receive TA consistently report a smoother onset, deeper visionary content, and more thorough physical detoxification. Purified HCL, on the other hand, allows for precise dosing based on body weight and provides the concentrated neurochemical reset that addresses receptor-level addiction pathways.

By combining the two, we achieve both the depth of traditional iboga healing and the precision of modern pharmacology. The booster doses — smaller amounts of HCL administered in the days following the flood dose — extend the therapeutic window and address any residual withdrawal symptoms or cravings that surface as the initial dose clears. This progressive approach means that patients do not experience the abrupt transition from "medicated" to "unmedicated" that can occur with single-dose protocols. The landing is gentler, the integration more stable, and the long-term outcomes, in our clinical observation, significantly better.

Day 2 and 3: Integration Begins The days immediately following the flood dose are a critical and often underappreciated part of the ibogaine experience. The medicine has opened a window — neuroplasticity is elevated, old patterns have been disrupted, and the patient is in a uniquely receptive psychological state. What happens in this window determines much of the long-term outcome. At MindScape, patients remain on-site for several days after treatment.

They participate in integration sessions with our clinical team, eat nutritious meals, rest in the Cozumel sunlight and ocean air, and begin to articulate what they experienced. Journaling is encouraged. Conversations with other patients — often people who have been through similar struggles — provide a sense of community and shared understanding that is profoundly healing in its own right. Physically, patients continue to feel the effects of noribogaine during this period.

Sleep patterns may be disrupted for a few days. Appetite returns gradually. There is sometimes a period of emotional sensitivity — tears come easily, both from grief and from gratitude. This is not a complication; it is the integration process working as it should.

The emotional material that was surfaced during the visionary phase needs to be felt, processed, and released. Suppressing it would defeat the purpose of the treatment. By day three, most patients report a sense of clarity and purpose that they describe as qualitatively different from anything they have experienced before. Opioid-dependent patients often note with astonishment that their withdrawal symptoms are gone — not managed, not reduced, but absent.

PTSD patients describe the traumatic memories as still present but no longer charged with the overwhelming emotional intensity that defined their daily existence. Depression patients speak of a lightness, a sense of possibility, that they had forgotten was available to them. The First Week: What to Expect The week following ibogaine treatment is a time of recalibration. The brain is actively reorganizing — forming new synaptic connections, consolidating the neuroplastic changes initiated by the medicine, and adjusting to a neurochemical landscape that has been fundamentally altered.

Patients should expect vivid dreams during this period. The dream content often mirrors or extends the themes of the ibogaine experience, as though the integration process continues during sleep. Energy levels fluctuate — some days feel charged with motivation and clarity, while others bring fatigue and emotional processing. This is normal.

The brain is doing important work, and it requires rest. We stay in contact with every patient during this period through our aftercare program. The insights gained during the ibogaine experience are powerful, but they require ongoing support to translate into lasting behavioral change. Therapy, lifestyle modifications, community connection, and in some cases microdosing protocols are all part of the post-treatment framework that turns a single profound experience into a sustained trajectory of healing.

What the Experience Is Really About If there is one thing I want every potential patient to understand, it is this: the ibogaine experience is not about having visions. The visions are a vehicle. They are the medium through which the medicine delivers its most important gift — the opportunity to see yourself clearly, perhaps for the first time since your suffering began. Addiction, trauma, depression — these conditions share a common feature.

They narrow the field of perception. They trap the mind in loops that feel inescapable. Ibogaine breaks those loops. It does so through measurable neurochemical mechanisms, but the subjective experience of that breaking is what patients remember.

It is the moment when the weight lifts, when the story you have been telling yourself about who you are and what is possible for you suddenly reveals itself as just that — a story. And stories can be rewritten. At MindScape Retreat, we have built an entire clinical infrastructure around that moment. The cardiac monitors, the nursing staff, the physicians, the combined TA and HCL protocol, the integration support — all of it exists to ensure that when that moment arrives, you are safe, supported, and ready to step through the door it opens.

If you are considering ibogaine treatment and want to understand whether it might be right for your situation, we invite you to reach out for a confidential consultation. Every journey begins with a conversation.

Schedule Your Free Consultation → mindscaperetreat

com/contact Dr. Omar Calderon, M.

is the Medical Director at MindScape Retreat in Cozumel, Mexico

He specializes in ibogaine-assisted detoxification and neurological recovery. References Alper, K. , Stajić, M. , & Gill, J.

(2012). Fatalities temporally associated with the ingestion of ibogaine. *Journal of Forensic Sciences*, 57(2), 398-412. Carhart-Harris, R.

, Roseman, L. , Haijen, E. , et al. (2018).

Psychedelics and the essential importance of context. *Journal of Psychopharmacology*, 32(7), 725-731. Glick, S. , Maisonneuve, I.

, & Szumlinski, K. (2001). Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer ibogaine congener. *The Alkaloids: Chemistry and Biology*, 56, 39-53.

Koenig, X. , & Hilber, K. (2015). The anti-addiction drug ibogaine and the heart: a delicate relation.

*Molecules*, 20(2), 2208-2228. Mash, D. , Kovera, C. , Pablo, J.

, et al. (2000). Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy results. *Annals of the New York Academy of Sciences*, 914(1), 394-401.

Schenberg, E. , de Castro Comis, M. , Chaves, B. , & da Silveira, D.

(2017). Treating drug dependence with the aid of ibogaine: a retrospective study. *Journal of Psychopharmacology*, 28(11), 993-1000.